5356-59-2

Usage

Uses

Used in Pharmaceutical Industry:
(3beta,5xi,18alpha)-3-(dodecanoyloxy)-11-oxoolean-12-en-29-oic acid is used as a potential therapeutic agent for its anti-inflammatory properties, aiming to alleviate inflammation-related conditions and diseases. Its antioxidant effects also contribute to its potential use in combating oxidative stress, which is implicated in various pathological conditions.
Used in Cancer Treatment Research:
In the field of oncology, (3beta,5xi,18alpha)-3-(dodecanoyloxy)-11-oxoolean-12-en-29-oic acid is being studied for its potential role in cancer treatment. Its ability to inhibit the growth of tumor cells suggests that it could be a valuable compound in developing new cancer therapies, particularly if its mechanisms of action can be fully understood and harnessed effectively.
Further research is necessary to explore the therapeutic potential and mechanisms of action of (3beta,5xi,18alpha)-3-(dodecanoyloxy)-11-oxoolean-12-en-29-oic acid, as well as to determine its safety and efficacy in various applications.

Upstream product

• 112-16-3 n-dodecanoyl chloride 
• 471-53-4 enoxolone 

Relevant academic research and scientific papers

Glycyrrhetinic acid and its analogs: A new class of antifilarial agents

Although a number of chemicals have been isolated from Glycyrrhiza glabra, only a few have been evaluated for their biological significance. As part of our drug discovery program for antifilarial agents from Indian medicinal plants, the roots of G. glabra were chemically investigated, which resulted in the isolation and characterization of an antifilarial agent, glycyrrhetinic acid (GA, 1a) effective against microfilariae (mf) in vitro (LC100: 12.5 μM; IC50: 1.20 μM), but was inactive against adult worms. Further, GA (1a) was converted into six analogs (2a-7a) and their antifilarial potential was evaluated by studying in vitro motility and MTT reduction assays employing mf and adult worms of Brugia malayi. The results showed that out of six GA analogs, the benzyl amide analog (6a) killed adults and mf at 25 and 50 μM concentration, respectively, and inhibited 49% MTT reduction potential of the adult parasites. The IC50 values were found to be 8.8 and 2.2 μM for adults and mf, respectively. The SI of the compound was >60. On the other hand the octylamide analog (7a) required much higher concentration to adversely affect the parasites. Finally, both active amide analogs (6a and 7a) were in vivo evaluated using B. malayi-jird model, which showed that analog 6a possesses promising macrofilaricidal activity at 100 mg/kg, s.c. ×5 days and around 40% of the treated animals showed calcified masses of worm fragments in peritoneal cavity of the animals. To the best of our knowledge this is the first ever report on the antifilarial potential of GA analogs. Further work on optimization of the antifilarial lead is under progress.